title: Surgical restaging of advanced Hodgkin's disease after first line chemotherapy.
abstract: 47 patients with stages IIIB and IV Hodgkin's disease underwent laparotomy with splenectomy as restaging procedure after first-line chemotherapy (CT) which included 4 cycles of CT ABV/IMEP/PCAV/ABV. After surgical restaging (SR), all patients were scheduled to receive 2 additional cycles IMEP/PCAV followed by TNI 20 Gy and patients with residual clinical abnormality or positive restaging surgery received a 20 Gy boost to these areas. 11 patients (23.4%) were found to have active disease in the spleen (10 patients) and/or the lymph nodes (3 patients) after SR. In the spleen, foci of active disease had a size in millimeters and confirm the limits of clinical restaging. According to the response to CT, 5 of the 35 patients (14%) clinically restaged as good responders had active disease; 6 of the 12 patients (50%) clinically restaged as poor responders had active disease. SR is of interest in selected patients with slowly responding disease to determine the indication of an extended field RT for responding patients and salvage therapy for patients resistant to CT.
authors.affiliation: Institut de Recherche d'Hématologie et d'Oncologie, Hôpital Saint-Louis, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Fermé
authors.forename: P
authors.initials: P
authors.lastname: Brice
authors.forename: E
authors.initials: E
authors.lastname: Bourstyn
authors.forename: M F
authors.initials: MF
authors.lastname: D'Agay
authors.forename: E
authors.initials: E
authors.lastname: Lepage
authors.forename: J M
authors.initials: JM
authors.lastname: Miclea
authors.forename: J P
authors.initials: JP
authors.lastname: Fermand
authors.forename: J M
authors.initials: JM
authors.lastname: Extra
authors.forename: J
authors.initials: J
authors.lastname: Frija
authors.forename: P
authors.initials: P
authors.lastname: Colin
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D001853:Bone Marrow / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006037:Glyoxal / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008099:Liver / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D009367:Neoplasm Staging; D011238:Prednimustine / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D013154:Spleen / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D006037:Glyoxal; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011238:Prednimustine; D007069:Ifosfamide